Lineage Cell Therapeutics
LCTX
LCTX
118 hedge funds and large institutions have $85.9M invested in Lineage Cell Therapeutics in 2019 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 44 increasing their positions, 20 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
12% more funds holding
Funds holding: 105 → 118 (+13)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.08% less ownership
Funds ownership: 44.95% → 43.87% (-1.1%)
Holders
118
Holding in Top 10
3
Calls
$98K
Puts
$83K
Top Buyers
| 1 | +$4.92M | |
| 2 | +$4.18M | |
| 3 | +$1.36M | |
| 4 |
NFC
Northeast Financial Consultants
Westport,
Connecticut
|
+$537K |
| 5 |
PCM
Price Capital Management
Lafayette,
Louisiana
|
+$430K |
Top Sellers
| 1 | -$715K | |
| 2 | -$528K | |
| 3 | -$301K | |
| 4 |
Renaissance Technologies
New York
|
-$237K |
| 5 |
JG
Jefferies Group
New York
|
-$173K |